Last reviewed · How we verify
NCT02455024: OMNI
An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®
trial in Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL in 3 participants. Terminated before completion.
19 February 2019
Quick facts
| Lead sponsor | Ariad Pharmaceuticals |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 3 |
| Start date | 2 March 2018 |
| Primary completion | 19 February 2019 |
| Estimated completion | 19 February 2019 |
| Sites | 2 locations across United States |
Conditions studied
- Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL — all drugs for Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL →
Sponsor
Ariad Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational registry to further characterize the safety profile of patients with chronic myeloid leukemia in the chronic phase (CP-CML), accelerated phase (AP-CML), blast phase (BP-CML), or Ph+ALL treated with Iclusig (ponatinib) in routine clinical practice in the US. The registry is focused on analysis of vascular occlusive events.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
Tan FH, Putoczki TL, Stylli SS, Luwor RB. · · 2019 · cited 142× · PMID 30705592 · DOI 10.2147/ott.s189391
Verify or expand the search:
- PubMed search for NCT02455024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ariad Pharmaceuticals trials
Trials by the same sponsor.
- NCT03535740 — A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Canc · Phase 2 · completed
- NCT02737501 — ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small · Phase 3 · completed
- NCT02627677 — A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia · Phase 3 · terminated
- NCT02094573 — A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, · Phase 2 · completed
- NCT01874665 — A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02455024 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ariad Pharmaceuticals
- Last refreshed: 4 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02455024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing